Today: 18 January 2026
Subscribe
Browse Category

Biotech News 22 October 2025 - 31 October 2025

Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Biotech Bombshell: Intensity Therapeutics (INTS) Surges Nearly 400% on Major Cancer Trial News

Stock Performance & Recent Market Reaction Intensity Therapeutics shares were flat-to-down during Oct. 2025 until the news, trading around $0.27 on Oct. 29 ts2.tech. On Oct. 30 (Thursday), publication of its trial in Lancet sent the stock parabolic: intraday it soared nearly 395%, closing at $1.32 Benzinga. In after-hours trading, the stock gave up much of the gain and traded…
31 October 2025
····
Apellis’ $458M Shocker: FDA Win, Analyst Buzz & 20% Stock Whiplash

Apellis’ $458M Shocker: FDA Win, Analyst Buzz & 20% Stock Whiplash

Blockbuster Quarter Meets Stock Turbulence Apellis Pharmaceuticals, a biotech focused on complement-mediated diseases Gurufocus, delivered standout financial results for the third quarter of 2025 – yet its stock took a beating. The company reported Q3 revenue of $458.6 million, more than doubling from $196.8 M in the same quarter last year Investing. This record top-line was boosted by a one-time $275 M licensing…
30 October 2025
···
Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Stock Rally on Novel Cancer Data Intensity Therapeutics (NASDAQ: INTS) has been one of the market’s biggest movers. On Oct. 30, 2025 its stock was around $0.27 per share Investing – an 84% drop YTD but up nearly 200% intraday on the news of its Lancet-published trial Tipranks. Trading volume exploded: ~279 million shares traded on Oct. 30 vs. an average of…
30 October 2025
···
Ernexa Therapeutics (ERNA) Skyrockets on Cancer Therapy Deal – Will Rally Last?

Ernexa Therapeutics (ERNA) Skyrockets on Cancer Therapy Deal – Will Rally Last?

ERNA Stock Soars on Cell Therapy Breakthrough Ernexa Therapeutics Inc. – a small Cambridge, MA biotech formerly known as Eterna Therapeutics – saw its stock skyrocket on October 29 after unveiling a major collaboration to advance its cutting-edge cancer therapy. By Wednesday afternoon, ERNA shares were up about 48% as investors piled in on news that Ernexa is partnering with…
29 October 2025
····
Profusa (PFSA) Stock Skyrockets 36% on Milestone News – Can This Biotech Sensor Play Rebound?

Profusa (PFSA) Stock Skyrockets 36% on Milestone News – Can This Biotech Sensor Play Rebound?

Milestone News: Manufacturing Boost and European Deals Profusa’s after-hours surge came on the heels of a positive company update. The California-based digital health firm announced it has completed key manufacturing initiatives, creating enough production capacity to supply more than twice the units needed to meet its 2026 revenue goals for the Lumee™ continuous oxygen sensor system Benzinga. Fred Knechtel, Profusa’s…
29 October 2025
····
Alexandria Real Estate Equities (ARE) Stock Plummets to 52-Week Low After Q3 Miss – Can the Biotech REIT Rebound?

Alexandria Real Estate Equities (ARE) Stock Plummets to 52-Week Low After Q3 Miss – Can the Biotech REIT Rebound?

Stock Nosedives on Earnings News Pasadena, Calif., Oct. 28, 2025 – Alexandria Real Estate Equities (NYSE: ARE) saw its stock price collapse to a new 52-week low in Tuesday’s trading, as disappointing quarterly results and lowered guidance fueled a sharp sell-off. By mid-afternoon, shares were down roughly 16% on the day around the mid-$60s Gurufocus, recovering slightly from an early dip…
28 October 2025
····
Co-Diagnostics (CODX) Stock Triples on Saudi JV Deal – Analysts See More Upside Ahead

Co-Diagnostics (CODX) Stock Triples on Saudi JV Deal – Analysts See More Upside Ahead

Shares Triple on Saudi JV News Co-Diagnostics stock exploded higher on Monday, triggered by an unexpected international deal. The small-cap diagnostics firm’s shares opened around $0.59 and skyrocketed, at one point up 133% by mid-morning ts2.tech. The rally accelerated throughout the day – by late morning CODX was +148% and still climbing amid wave after wave of retail buying ts2.tech.…
28 October 2025
···
Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Bottom Line: Avidity Biosciences’ stock is set to explode higher on Novartis’s $12 billion buyout, capping off a dramatic run fueled by breakthrough science and takeover buzz. The high-premium deal underscores the massive value of RNA therapeutics for rare diseases – and signals that big pharma’s biotech spending spree isn’t slowing down. While Avidity’s chapter as an independent company is…
26 October 2025
···
Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Theriva Biologics (TOVX) Stock Surges on Cancer Trial Breakthrough – What’s Next?

Theriva’s Stock Swing: In mid-October, Theriva’s Nasdaq-traded shares spiked on news of clinical success. On Oct. 15 the stock jumped from roughly $0.44 to $0.84 intraday ts2.tech, an increase of about 92%. This surge coincided with reports that VCN-01 had met the primary endpoints in the VIRAGE Phase 2b trial (see below). The very next trading day, Theriva disclosed a…
24 October 2025
····
Neuphoria Stock Crashes After Social Anxiety Trial Failure — What’s Next?

Neuphoria Stock Crashes After Social Anxiety Trial Failure — What’s Next?

Key Facts: – Neuphoria (Nasdaq: NEUP) shares plunged ~67% in after-hours trading on Oct 20 when its lead drug BNC210 failed a Phase 3 SAD trial Investing. The AFFIRM-1 trial missed both primary and secondary endpoints, and the company immediately halted its social anxiety program and launched a full strategic review Investing Globenewswire. – CEO Spyros Papapetropoulos vowed to “conserve…
24 October 2025
···
Armata (ARMP) Stock Surges 150% After Breakthrough Bacteriophage Trial Results

Armata (ARMP) Stock Surges 150% After Breakthrough Bacteriophage Trial Results

Armata’s stock performance this week has been nothing short of dramatic. Prior to Oct. 22, ARMP had been trading in the low-$3 range (for example, it closed around $3.41 on Oct. 16 Marketbeat). Once the late-breaking IDWeek data was announced, the shares rocketed – briefly hitting an intraday high near $16 (per some quotes) before settling at about $8.87 Finviz…
22 October 2025
···
Thermo Fisher Stock Skyrockets – Biotech Boom & Big Deals Fuel Rally, Analysts Eye $650

Thermo Fisher Stock Skyrockets – Biotech Boom & Big Deals Fuel Rally, Analysts Eye $650

Stock Performance and Sector Rally Thermo Fisher’s stock price has surged in recent weeks on renewed investor optimism. After a slow start to 2025 (even a ~10% year-over-year dip early in the year), the stock turned higher in October. TS2.Tech notes the stock “rallied strongly in recent weeks – up over 11% in October after a slower start to the…
22 October 2025
····
1 … 6 7 8 9 10 … 12

Stock Market Today

  • Q3 Media Earnings: fuboTV Leads as Group Beats Estimates; WMG and WBD Mixed
    January 18, 2026, 3:28 PM EST. Q3 media earnings show resilience amid secular headwinds. Seven tracked stocks beat revenue estimates by an average of 2.1%, and shares rose about 6.2% on the quarter. The standout was fuboTV, which posted revenue of $377.2 million, down 2.3% year over year but topping consensus by 4.9%; the company also beat EPS and EBITDA forecasts, though the stock has fallen 28.9% since results and trades near $2.69. Warner Music Group delivered revenue of $1.87 billion, up 14.6% YoY and topping estimates by 10.8%; the stock rose about 1.2% to $30.88. By contrast, Warner Bros. Discovery reported revenue of $9.05 billion, down 6% YoY and missing content revenue estimates by 1.9%, but beat adjusted operating income expectations; the stock has risen 24.5% to around $28.52.
Go toTop